Leading Product Revenue

February 9, 2026

(¥ million)

Brand name	Active Ingredient	Indications	Launch Date	Sales FY2023 (IFRS)	Sales FY2024 (IFRS)	Sales FY2025 (IFRS)
Brand name	Active Ingredient	Indications	Launch Date	Sales FY2023 (IFRS)	Sales FY2024 (IFRS)	Apr.-Dec.	Annual (estimated)
Viltepso				17,530	21,782	15,877	21,200
(Japan)	viltolarsen	Duchenne muscular dystrophy	Japan May-2020 U.S. Aug-2020	(4,407)	(4,664)	(3,685)	(4,800)
(U.S.)				(13,123)	(17,117)	(12,192)	(16,400)
Uptravi	selexipag	pulmonary arterial hypertension/ chronic thromboembolic pulmonary hypertension	Nov-2016/ Aug-2021	12,918	14,971	13,188	17,300
Vyxeos	daunorubicin / cytarabine	high-risk acute myeloid leukemia	May-2024	-	5,139	4,562	6,000
Gazyva	obinutuzumab	CD20-positive follicular lymphoma/ CD20-positive chronic lymphocytic leukemia	Aug-2018/ Dec-2022	4,695	4,821	3,950	5,000
Fintepla	fenfluramine hydrochloride	seizures associated with Dravet syndrome/ seizures associated with Lennox-Gastaut syndrome	Nov-2022	377	2,067	3,098	4,200
Erleada	apalutamide	prostate cancer	May-2019	-	-	3,039	6,300
Vidaza	azacitidine	myelodysplastic syndrome/ acute myeloid leukemia	Mar-2011/ Mar-2021	10,383	5,109	2,624	3,200
Defitelio	defibrotide sodium	sinusoidal obstruction syndrome	Sep-2019	2,221	2,364	2,090	2,500
Tramal, Onetram	tramadol hydrochloride	cancer pain, chronic pain	Sep-2010	3,927	2,728	1,846	2,200
Cialis	tadalafil	erectile dysfunction	Jul-2009	2,499	2,425	1,753	2,300
CAP-1002 (U.S.)	deramiocel	Duchenne muscular dystrophy cardiomyopathy	Filed	-	-	-	-
Profit in co-promotion				8,658	9,170	7,082	9,000
Revenues from the licensing of industrial property rights				40,304	45,585	36,802	49,000
Pharmaceuticals				125,105	138,654	110,194	147,500
Functional Food				23,150	21,577	16,941	22,500
Revenue				148,255	160,232	127,135	170,000

Brand name	Active Ingredient	Indications	Launch Date	Sales FY2023 (IFRS)	Sales FY2024 (IFRS)	Sales FY2025 (IFRS)
Brand name	Active Ingredient	Indications	Launch Date	Sales FY2023 (IFRS)	Sales FY2024 (IFRS)	Apr.-Dec.	Annual (estimated)
Viltepso				17,530	21,782	15,877	21,200
(Japan)	viltolarsen	Duchenne muscular dystrophy	Japan May-2020 U.S. Aug-2020	(4,407)	(4,664)	(3,685)	(4,800)
(U.S.)				(13,123)	(17,117)	(12,192)	(16,400)
Uptravi	selexipag	pulmonary arterial hypertension/ chronic thromboembolic pulmonary hypertension	Nov-2016/ Aug-2021	12,918	14,971	13,188	17,300
Vyxeos	daunorubicin / cytarabine	high-risk acute myeloid leukemia	May-2024	-	5,139	4,562	6,000
Gazyva	obinutuzumab	CD20-positive follicular lymphoma/ CD20-positive chronic lymphocytic leukemia	Aug-2018/ Dec-2022	4,695	4,821	3,950	5,000
Fintepla	fenfluramine hydrochloride	seizures associated with Dravet syndrome/ seizures associated with Lennox-Gastaut syndrome	Nov-2022	377	2,067	3,098	4,200
Erleada	apalutamide	prostate cancer	May-2019	-	-	3,039	6,300
Vidaza	azacitidine	myelodysplastic syndrome/ acute myeloid leukemia	Mar-2011/ Mar-2021	10,383	5,109	2,624	3,200
Defitelio	defibrotide sodium	sinusoidal obstruction syndrome	Sep-2019	2,221	2,364	2,090	2,500
Tramal, Onetram	tramadol hydrochloride	cancer pain, chronic pain	Sep-2010	3,927	2,728	1,846	2,200
Cialis	tadalafil	erectile dysfunction	Jul-2009	2,499	2,425	1,753	2,300
CAP-1002 (U.S.)	deramiocel	Duchenne muscular dystrophy cardiomyopathy	Filed	-	-	-	-
Profit in co-promotion				8,658	9,170	7,082	9,000
Revenues from the licensing of industrial property rights				40,304	45,585	36,802	49,000
Pharmaceuticals				125,105	138,654	110,194	147,500
Functional Food				23,150	21,577	16,941	22,500
Revenue				148,255	160,232	127,135	170,000

Back Number

Related Link

Nippon Shinyaku’s DNA

Research & Development

Business/Financial Information